IPMN – Medxy AI

Sustained Quality of Life After Pancreatic Surgery for IPMNs in Young Patients: Long-Term Data and Clinical Implications

By MedXY 07/11/2026

Young patients undergoing resection for intraductal papillary mucinous neoplasms (IPMNs) exhibit excellent long-term quality of life comparable to the general population despite endocrine and exocrine insufficiencies.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population

By MedXY 06/01/2026

A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY 06/01/2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

Gastroenterology news Oncology

Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants

By MedXY 12/23/2025

A large-scale cohort study demonstrates that mixed-type IPMNs have a three-fold higher prevalence of high-risk mutations compared to branch-duct variants, and that cyst fluid NGS provides superior diagnostic specificity over traditional clinical imaging features.